Novartis' drug for a rare muscle-wasting disease failed in late-stage studies, marking the company's third clinical trial setback in a week. The drug, a core asset from Novartis' $12 billion acquisition of Avidity Biosciences, sparked concerns about its growth prospects following this failure.